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OBJECTIVE — The first sign of diabetic nephropathy is microalbuminuria, but its predictive
role of progression to overt nephropathy in type 2 diabetes has not yet been clarified. The aims
of this study were to assess during 7 years of follow-up the incidence rate of overt nephropathy
and the predictive role of microalbuminuria and other baseline variables (blood pressure, lipids,
fibrinogen, uric acid, smoking, and HbA1c cumulative average during follow-up).
RESEARCH DESIGN AND METHODS — A prospective population-based study was
performed in Casale Monferrato, Italy, including 1,253 type 2 diabetic patients recruited at
baseline (1991–1992), 765 with normoalbuminuria (albumin excretion rate [AER] 20 g/
min) and 488 with microalbuminuria (AER 20–200 g/min). All measurements were central-
ized. A nested case-control study within the cohort was performed, selecting four control
subjects, frequency matched for age and attained individual time of follow-up with each case.
Conditional regression analysis was performed to assess variables independently associated with
risk of progression to overt nephropathy.
RESULTS — Of 1,253 total patients, 1,103 (88.0%) were included in the follow-up exami-
nation (median 5.33 years); their age and duration of disease at baseline were 68.4 10.5 years
and 10.4  6.6 years, respectively. Cases of overt nephropathy were 202, giving an incidence
rate of 37.0/1,000 person-years (95% CI 32.3–42.6). In conditional logistic regression analyses,
microalbuminuria provided a 42% increased risk with respect to normoalbuminuria (95% CI
0.98–2.06), independently of duration of diabetes, hypertension, and systolic blood pressure.
Other variables independently associated with progression to overt nephropathy were HbA1c
cumulative average (P 0.002), apolipoprotein B (P 0.013), fibrinogen (P 0.02), and HDL
cholesterol (P  0.03).
CONCLUSIONS — Of type 2 diabetic patients, 3.7% progress every year to overt nephrop-
athy. Microalbuminuria is associated with a 42% increased risk of progression to overt nephrop-
athy. Other independent predictors are HbA1c, HDL cholesterol, apolipoprotein B, and
fibrinogen.
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T emporal trends of end-stage renaldisease (ESRD) caused by diabeticnephropathy are increasing world-
wide, so that diabetes represents the sec-
ond leading cause of dialysis in most centers
(1,2). The first sign of renal involvement
is microalbuminuria, which affects 20–
40% of patients with type 2 diabetes (3).
When macroalbuminuria occurs, glomeru-
lar filtration rate declines, with an average
reduction of 10–12 ml  min1  year1
(3).
The predictive role of microalbumin-
uria in progression to overt nephropathy
in type 2 diabetes has not yet been clari-
fied, however (4–6). With respect to pre-
vious studies, more recent ones have
suggested a lesser predictive role (5,6). A
benefit of lipid-lowering treatment on
risk of progression to overt nephropathy
has also been hypothesized (7). Abnor-
malities in lipoprotein metabolism, such
as elevations in triglycerides and apoli-
poprotein B (apoB) and reduced HDL
cholesterol, have been shown in mi-
croalbuminuric type 2 diabetic patients
(7,8). The clinical relevance of these alter-
ations on progression to overt nephro-
pathy, however, has not yet been estab-
lished. Most of the studies are limited by
the recruitment of either a low number of
clinic-based rather than population-
based patients or selected ethnic groups at
higher risk for nephropathy than Cauca-
sians (5,9–13). We have previously iden-
tified in Casale Monferrato, Italy, a large
population-based cohort of type 2 dia-
betic patients, who were characterized as
normo-, micro-, and macroalbuminuric
(14,15). The aims of this study were to
assess during a 7-year follow-up of this
cohort the incidence rate of overt ne-
phropathy and the predictive role of mi-
croalbuminuria and other baseline
variables (blood pressure, lipids, fibrino-
gen, uric acid, and smoking), indepen-
dent of HbA1c cumulative average during
follow-up.
RESEARCH DESIGN AND
METHODS — The study base was
1,253 patients (765 normoalbuminuric
and 488 microalbuminuric) with known
type 2 diabetes, residing in 1988 in the
town of Casale Monferrato, in the north-
west of Italy (93,477 inhabitants), and in-
vited at a baseline examination in 1991–
1992 to assess the prevalence of cardio-
vascular risk factors (14–16). They were
identified by using multiple sources of as-
certainment: 1) diabetes clinic, 2) general
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practitioners, 3) hospital discharges, 4)
prescriptions, and 5) sale records of re-
agent strips and syringes (17). Patients ex-
clusively cared for by their general
practitioners were 23.8% of the cohort
(18). A high estimated completeness of
ascertainment was obtained (19). A com-
parative assessment of surveys conducted
within Italy showed they were represen-
tative of Italian diabetic patients as re-
gards age, sex, duration of diabetes, BMI,
and pattern of antidiabetic treatment
(20).
All patients were interviewed and ex-
amined by three investigators after a train-
ing period to standardize data collection
and blood pressure measurement. In-
formed consent was obtained from all pa-
tients. Height and weight were measured
in indoor clothing without shoes with a
beam balance and a stadiometer, and BMI
was calculated. Blood pressure was mea-
sured with mercury sphygmomanome-
ters to the nearest 2 mmHg, in the right
arm at the start of examination, in sitting
position, three consecutive times after an
initial 5-min rest. Reported values are the
average of second and third readings
(phase 1 for systolic and phase 5 for dia-
stolic). Hypertension was defined as sys-
tolic blood pressure 140 mmHg,
diastolic blood pressure 90 mmHg, or
treatment with antihypertensive drugs.
Venous blood samples were collected in
the fasting state for determinations of
plasma glucose, triglycerides, total cho-
lesterol, uric acid (enzymatic-colorimetric
methods), HDL cholesterol (enzymatic-
colorimetric method, after precipitation
with Mn2), apoA1 and apoB (turbidi-
metric method; BM/hitachi 717, BBR), fi-
brinogen (Clauss method), and HbA1c
(high-performance liquid chromatogra-
phy; Daiichi; laboratory reference range
3.8–5.5%). Urinary albumin concentra-
tion was measured by a nephelometric
method (Behring Nephelometer Ana-
lyzer; Behring Institute) from a timed
overnight collection after having ex-
cluded urinary tract infections, conges-
tive heart failure, and other known causes
of renal diseases. Albumin excretion rate
(AER) was calculated as the albumin con-
centration divided by timed urine vol-
ume. A single measurement of AER was
performed at baseline.
Smoking habit was classified into one
of three categories: never smoker, ex-
smoker (stopped at least 1 month before
the visit), and smoker. Duration of diabe-
tes was defined as the time from diabetes
diagnosis to the time of baseline examina-
tion (1991–1992). Standard supine 12-
lead electrocardiograms (ECGs) were
recorded and read according to the Min-
nesota code criteria in duplicate (21).
Coronary heart disease (CHD) was de-
fined by ECG abnormalities, including
probable (major Q and QS items, codes
1.1 and 1.2) and possible (minor Q and
QS items, S-T/T items, codes 1.3, 4.1–
4.4, 5.1–5.3) indications of CHD
together. RR and QT intervals were mea-
sured in five consecutive cycles on lead
V5 of the resting ECG using a graduated
lens.
During the follow-up period (1991–
1997), patients were examined three to
four times a year at the diabetes clinic or
by general practitioners, according to
physician scheduled plans, with central-
ized laboratory measurements. In 1996–
1997, all living patients were reexamined
to assess progression to overt nephropa-
thy (AER 200 g/min in at least two
consecutive overnight urine collections).
For patients who died or migrated from
the area, the last measurements of AER
were obtained from computerized files of
the central laboratory. Cumulative indi-
vidual averages of HbA1c during fol-
low-up were calculated. Differences in
clinical characteristics of patients were as-
sessed using the t test for continuous vari-
ables and 2 test for ordinal variables;
results are shown as mean (SD) and geo-
metric mean (interquartile range) for nor-
mally and nonnormally distributed
variables, respectively. Incidence rates
were calculated by dividing the number of
new cases occurring during the study
period by the number of person-years of
observations. The time period was calcu-
lated from the baseline study to the fol-
low-up examination or to the last
examination if patient had died or had
moved from the area.
At baseline, the Casale Monferrato
Study recruited a prevalence cohort of pa-
tients, i.e., a heterogeneous cohort as re-
gards duration of disease and stage of
complications. The severity affecting
baseline factors is associated with selec-
tive mortality of the cohort, and the ex-
pected effect on our study was lower
attained individual time of follow-up (the
lag between baseline and reference exam-
ination) of more severe patients (22).To
take into account this effect, which would
have biased our results, we performed a
nested case-control study within the co-
hort of Casale Monferrato, selecting four
control subjects (subjects who did not
progress to overt nephropathy during fol-
low-up), frequency matched for age and
attained time of follow-up with each case
(subjects who progressed to overt ne-
phropathy during follow-up). By doing
so, we compared predictors of progres-
sion to overt nephropathy in subsets of
case and control subjects having similar
age and followed for an equal period of
time. Conditional regression analysis was
then performed to assess variables inde-
pendently associated with risk of progres-
sion to overt nephropathy. Continuous
variables were categorized in quartiles of
their distribution. The –2 log likelihood
ratio test was used to test the significance
of variables. The possible interactions be-
tween variables were assessed. All analy-
ses were performed using Stata (Stata
Release 7.0; Stata Corporation).
RESULTS — Of 1,253 patients with
normo- or microalbuminuria not caused
by other diseases at baseline examination,
1,103 were recruited during follow-up,
677 of 765 (88.5%) normoalbuminuric
and 426 of 488 (87.3%) microalbumin-
uric. Patients lost to follow-up were those
who died without centralized assess-
ments of AER (n  53 normoalbumin-
uric, n 57 microalbuminuric), migrated
from the area (n  18), or refused to be
retested (n  22).
At the baseline examination, mi-
croalbuminuric subjects were treated
more often with insulin and had higher
values of HbA1c, triglycerides, fibrinogen,
creatinine, and systolic and diastolic
blood pressure than normoalbuminuric
patients (Table 1). The distribution of
AER values in the cohort was skewed,
with mean 28.8g/min, median 15.7g/
min, and interquartile range 9.38–28.12.
During the follow-up period (median
5.33 years, range 0.05–7.86), 202 cases of
overt nephropathy were identified of
5,452.7 person-years of observations,
giving an incidence rate of 37.0/1,000
person-years (95% CI 32.3– 42.6); of
those, 84 were normoalbuminuric and
118 microalbuminuric at baseline, giving
incidence rates per 1,000 of 25.8 (95% CI
20.9 –32.0) and 53.6 (95% CI 44.7–
64.2), respectively. Relative risk (RR) of
progression to overt nephropathy was
twofold higher in micro- than in nor-
moalbuminuric patients (2.07, 95% CI
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1.57–2.74; P  0.0001), partially be-
cause of the effect of duration of diabetes
(adjusted RR 1.75, 95% CI 0.95–3.23;
P  0.07). Patients who died during fol-
low-up were 85 of 677 (12.6%) nor-
moalbuminuric and 76 of 426 (17.8%)
microalbuminuric patients (P  0.016).
At the baseline examination, patients
who developed overt nephropathy were
older (71.8 10.7 vs. 66.8 10.1 years;
P  0.001) and had a longer duration of
diabetes (11.8 7.8 vs. 10.0 6.3 years)
than nonprogressors. In addition, they
had higher values of cumulative average
HbA1c (7.7  2.0 vs. 7.3  1.6%; P 
0.001) and fibrinogen (3.79  0.89 vs.
3.55  0.90 g/dl; P  0.001) and lower
values of total cholesterol (5.63  1.36
vs. 5.83  1.18 mmol/l; P  0.046) and
HDL cholesterol (1.35 0.42 vs. 1.46
0.46 mmol/l; P  0.001) but similar val-
ues of other metabolic variables.
No differences between progressors
to overt nephropathy and nonprogressors
were found at baseline in either systolic
blood pressure (155.2 27.0 vs. 153.5
22.1 mmHg; P 0.35) or diastolic blood
pressure (86.5  13.6 vs. 87.4  10.7;
P  0.30). Even at the follow-up exami-
nation, blood pressure values were simi-
lar (150.9 20.3 and 83.3 9.7 mmHg
in progressors; 148.5 18.5 and 83.2
8.9 mmHg in nonprogressors); both sys-
tolic and diastolic blood pressure values,
however, were lower than at baseline.
In patients treated for hypertension,
frequencies of treatments were slightly
different at baseline (n  555 patients)
than at follow-up (n 610 patients): 42.2
vs. 61.2% were treated with ACE inhibi-
tors, either alone or in combination with
other drugs; 6.3 vs. 12.0% were treated
with Ca2 antagonists, 21.1 vs. 10.0%
with diuretics, 4.1 vs. 3.1% with 	-block-
ers, 20.0 vs. 5.7% with vasodilators or alfa
adrenergic inhibitors, and 6.3 vs. 8.0%
with two or more drugs in combination.
Frequencies were similar in subgroups
defined by AER categories at baseline and
in patients cared for by general practitio-
ners, apart from treatment with ACE in-
hibitors, which was more frequent at
baseline (25.1 vs. 10.0%; P 0.002) and
at follow-up (42.5 vs. 28.9%; P 0.02) in
microalbuminuric patients cared for by
diabetes clinics. Frequencies of treatment
for hyperlipidemia were similar at base-
line and at follow-up examinations (5.4
vs. 5.9%) in the whole cohort as well as in
subgroups defined by AER categories.
In nested case-control analyses, 202
case subjects and 785 control subjects,
frequency matched for age and attained
time of follow-up, were compared. In uni-
variate analyses we showed increased, al-
though not statistically significant, odds
ratios (ORs) for progression in patients
treated with insulin (OR 1.43, 95% CI
0.82–2.48) and smokers (OR 1.31, 95%
CI 0.81–2.13). No effects of hypertensive
status, systolic or diastolic blood pres-
sure, CHD, or treatment with ACE in-
hibitors were evident. The OR for
macroalbuminuria was 1.55 (95% CI
1.11–2.16). The upper quartile of HbA1c
cumulative individual average (values
8.3%) had OR 1.66 (95% CI 1.08 –
2.55) versus the lowest quartile (values
6.2%). As regards fibrinogen, increased
ORs for progression were found in the
upper quartiles (OR 1.94, 95% CI 1.23–
3.07, for values between 3.49 and 4.12
g/l; OR 1.56, 95% CI 0.97–2.52, for val-
ues 4.12; reference values 3.00 g/l).
As regards lipids, a decreasing trend
of ORs for increasing values of HDL was
evident (OR 0.50, 95% CI 0.32–0.76, for
values between 1.35 and 1.60 mmol/l; OR
0.57, 95% CI 0.30 – 0.72, for values
1.60 mmol/l; reference values 1.14
mmol/l). Higher values of triglycerides
were associated with risk of progression
(OR 1.27, 95% CI 0.80–2.00, for values
between 1.44 and 2.03 mmol/l; OR 1.60,
95% CI 1.01–2.52, for values 2.03
mmol/l; reference values1.07 mmol/l).
In multivariate conditional logistic re-
gression analyses (Table 2), after having
taken into account the effects of con-
founders (duration of diabetes) and
known risk factors for overt nephropathy
(hypertension, systolic blood pressure,
and cumulative individual average of
HbA1c), microalbuminuria provided a
42% increased risk of progression with
respect to normoalbuminuria (95% CI
0.98–2.06; P 0.06). Other variables in-
dependently associated with progression
to overt nephropathy were HbA1c cumu-
lative average (P  0.002), apoB (P 
0.013), fibrinogen (P  0.02), and HDL
cholesterol (P  0.03). No effect of tri-
Table 1—Baseline characteristics of normo- and microalbuminuric patients of the Casale
Monferrato Study recruited for follow-up
Normoalbuminuric Microalbuminuric P
n 677 426
Age (years) 67.2  10.0 67.9  10.6 0.22
Men 273 (40.3) 204 (47.9) 0.01
Duration of diabetes (years) 9.8  6.3 11.1  7.0 0.001
BMI (kg/m2) 27.4  4.8 27.8  4.8 0.20
Antidiabetic treatment
Diet 98 (14.5) 30 (7.1) 0.0001
Oral drugs 496 (73.5) 299 (70.7)
Insulin 81 (12.0) 94 (22.2)
CHD 123 (21.5) 84 (23.7) 0.43
Smoker 89 (13.4) 60 (14.4) 0.02
Ex-smoker 119 (18.0) 103 (24.7)
Nonsmoker 454 (68.6) 254 (60.9)
Hypertension 554 (81.8) 363 (85.2) 0.08
Systolic blood pressure (mmHg) 153.1  21.1 156.1  22.5 0.03
Diastolic blood pressure (mmHg) 87.0  10.0 88.3  10.7 0.03
Treatment with ACE inhibitors 140 (20.7) 94 (22.1) 0.58
HbA1c (%) 7.8  2.3 8.4  2.3 0.0001
Total cholesterol (mmol/l) 5.81  1.20 5.80  1.25 0.85
HDL cholesterol (mmol/l) 1.46  0.43 1.42  0.52 0.26
Triglycerides (mmol/l) 1.44 (1.02–1.91) 1.55 (1.07–2.15) 0.02
ApoA1 (mg/dl) 137.1  35.5 131.8  29.8 0.01
ApoB (mg/dl) 101.6  35.0 102.2  38.6 0.79
Fibrinogen (g/l) 3.55  0.87 3.69  0.97 0.01
Uric acid (mol/l) 313  92 323  92 0.09
Creatinine (mol/l) 88 (74–97) 90 (80–104) 0.007
Data are means  SD, n (%), or medians (interquartile range).
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glycerides was evident after including
HDL cholesterol in the model.
CONCLUSIONS — This study was
addressed to investigate the association
between microalbuminuria and the inci-
dence of overt nephropathy in a 7-year
follow-up of a type 2 diabetic cohort of
Casale Monferrato. We provide evidence
that patients with microalbuminuria have
a 42% increased risk of progression to
overt nephropathy versus those with nor-
moalbuminuria, even after adjustment for
confounders (age, duration of diabetes,
and attained time of follow-up) and risk
factors (blood pressure and cumulative
HbA1c average). We found that 3.7% of
diabetic patients progress every year to
overt nephropathy, 2.6% among nor-
moalbuminuric and 5.4% among mi-
croalbuminuric patients. These estimates
are consistent with those obtained in pre-
vious studies (4,12). Although numerous
investigators have reported the associa-
tion between microalbuminuria and the
risk of diabetic nephropathy, few studies
have been carried out in large population-
based cohorts of Caucasians with type 2
diabetes (4,12). In addition, most studies
were limited to patients younger than 65
years. The Casale Monferrato cohort is
representative of the Italian diabetic pop-
ulation, being characterized by both bet-
ter glycemic control than those generally
recruited in Northern European countries
and later age at diagnosis; 50% of patients
recruited in this study were 68 years and
older at baseline. Our finding that mi-
croalbuminuria is associated with an in-
creased risk of overt nephropathy even in
the elderly is relevant, highlighting that
microalbuminuria is never a benign con-
dition and that it should be carefully pre-
vented at any age, in view of the effective
intervention measures (3).
When we analyzed in a multivariate
model the contribution of each risk factor
adjusting for all the others, HDL choles-
terol, apoB, and fibrinogen remained as
independent risk factors, whereas the as-
sociation with triglycerides disappeared.
These results, therefore, provide evidence
that HDL, apoB, and fibrinogen are per se
predictors of progression to overt ne-
phropathy, independently of the pres-
ence of microalbuminuria or hyperten-
sion. These findings are consistent with
previous studies (7,23) and could at least
partially explain the excess of cardiovas-
cular morbidity and mortality of mac-
roalbuminuric patients (24). Whether
these findings reflect lipid abnormalities
characterizing the earlier phases of dia-
betic nephropathy, or their direct in-
volvement in its progression, is unknown.
We did not find any association be-
tween hypertensive status and progres-
sion to overt nephropathy. This finding,
however, should be considered with cau-
tion considering that the prevalence of
hypertension in this cohort was very high
(80%), thus reducing the power to detect
a significant effect of this variable. More-
over, blood pressure values at the fol-
low-up examination were lower than at
baseline, and a more aggressive approach
to treatment of hypertension might have
blunted its predictive effect on progres-
sion to overt nephropathy.
An association between smoking and
loss of renal function has been shown in
type 1 diabetes (25) and nondiabetic sub-
jects (26), whereas no convincing data are
available for type 2 diabetes (12). Consis-
tently, we did not find a predictive role of
smoking on risk of progression to overt
nephropathy.
The prospective study design, the
large population sample, and the high de-
gree of longitudinal surveillance for dia-
betic nephropathy are strengths of the
present study. At variance with previous
studies, we dedicated great efforts to re-
duce selection bias by recording AER and
Table 2—Results of conditional logistic regression analyses of variables associated with pro-
gression to overt nephropathy in the Casale Monferrato Study
OR (95% CI)
Duration (years)
5.5 1.00
5.5–8.5 1.10 (0.67–1.80)
8.6–14.9 1.44 (0.89–2.35)
14.9 1.39 (0.85–2.28)
Hypertension
No 1.00
Yes 0.67 (0.35–1.28)
Systolic blood pressure (mmHg)
140 1.00
141–152 0.87 (0.47–1.60)
153–170 1.53 (0.87–2.68)
170 1.21 (0.67–2.18)
AER
Normoalbuminuria 1.00
Microalbuminuria 1.42 (0.98–2.06)
HbA1c cumulative average (%)
6.16 1.00
6.16–7.37 0.52 (0.31–0.88)
7.38–8.32 0.67 (0.40–1.12)
8.32 1.26 (0.78–2.03)
Fibrinogen (g/l)
3.00 1.00
3.00–3.48 1.07 (0.63–1.83)
3.49–4.12 1.93 (1.18–3.16)
4.12 1.54 (0.92–2.58)
HDL cholesterol (mmol/l)
1.14 1.00
1.14–1.34 0.56 (0.34–0.93)
1.35–1.60 0.55 (0.34–0.87)
1.60 0.54 (0.33–0.89)
ApoB (mg/dl)
74 1.00
74–94 0.82 (0.48–1.40)
95–122 1.73 (1.05–2.87)
122 1.34 (0.81–2.24)
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HbA1c data of both living and dead pa-
tients, which were retrospectively ex-
tracted from the computerized files of the
central laboratory. By using this method,
we were able to provide a high degree of
completeness of data at follow-up (88%).
In addition, considering that attained in-
dividual time of follow-up (that is lag
between baseline and reference examina-
tion) is associated with prognostic factors,
which are likely to be stratified differently
among normo- and microalbuminuric
patients, a case-control analysis within
the cohort was performed, matching case
subjects (progressors) and control sub-
jects (nonprogressors) for age and at-
tained time of follow-up. Conditional
logistic regression analysis of the case-
control study design gave very different
results from the unconditional logistic re-
gression of the cohort study design. In the
latter, the role of microalbuminuria was
overemphasized, with a threefold in-
creased risk with respect to normoalbu-
minuria (data not shown). This point is
critical to state the strength of predictors
and to compare results of different studies
on this issue (22).
The main limitation of the study is the
use of a single AER measurement at base-
line, because it might have caused a mis-
classification of patients with regard to
micro- and macroalbuminuria. However,
this finding would have caused a bias to-
ward the null value, that is, the underes-
timation of the strength of the relation-
ship between microalbuminuria and the
incidence of overt nephropathy. In
30%
of patients with type 2 diabetes and mi-
croalbuminuria but no retinopathy, the
glomerular structure is normal or nondi-
abetic kidney diseases are present (27).
Variability in the progression of renal dis-
ease has also been suggested, with more
rapid loss of function in patients with typ-
ical diabetic glomerulopathy (28). Unfor-
tunately, no data on retinopathy were
available at baseline in the Casale Monfer-
rato cohort to test this hypothesis.
In conclusion, our population-based
study extends previous observations in
several ways. First, we provide evidence
that 3.7% of type 2 diabetic patients
progress every year to overt nephropathy;
second, we confirm the predictive role of
microalbuminuria, which is associated
with a 42% increased risk of progression;
third, we show that HDL cholesterol,
HbA1c, apoB, and fibrinogen are indepen-
dently associated with risk of progression.
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